Fetal hemoglobin chemical inducers for treatment of hemoglobinopathies

Annals of Hematology

Volumn 88, Issue 6, 2009, Pages 505-528

  Testa, Ugo ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Anemia; Hemoglobin; Sickle cell disease; Thalassemia

Indexed keywords

4 PHENYLBUTYRIC ACID; 5 AZA 2' DEOXYCYTIDINE; ARGININE BUTYRATE; AZACITIDINE; BETA GLOBIN; BUTYRIC ACID; CCAAT ENHANCER BINDING PROTEIN; CIS ACTING ELEMENT; DEXAMETHASONE; ERYTHROID KRUPPEL LIKE FACTOR; ERYTHROPOIETIN; HEMOGLOBIN F; HEREDITARY PERSISTENCE OF FETAL HEMOGLBIN; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA; KRUPPEL LIKE FACTOR; LENALIDOMIDE; PLACEBO; POMALIDOMIDE; PROTEIN BCL11A; RB 7; RECOMBINANT STEM CELL FACTOR; STEM CELL FACTOR; THALIDOMIDE; TRANS ACTING FACTOR; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR NF E2; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; ZINC FINGER PROTEIN;

ACETYLATION; ANGIONEUROTIC EDEMA; BETA THALASSEMIA; BINDING SITE; BODY HEIGHT; CELL DIFFERENTIATION; CHROMATIN; CHROMOSOME 2P; CHROMOSOME 6Q; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; CODON; CORFU DELETION; CUTANEOUS ANGIOEDEMA; DEVELOPMENTAL STAGE; DNA METHYLATION; DRUG ABSORPTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; ERYTHROID CELL; ERYTHROPOIESIS; GENE DELETION; GENE EXPRESSION REGULATION; GENE LOCUS; GENE SILENCING; GENE SWITCHING; GENE THERAPY; GENETIC REGULATION; GENETIC TRANSCRIPTION; GLOBIN GENE; GLOBIN SYNTHESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN SYNTHESIS; HEMOGLOBINOPATHY; HISTONE ACETYLATION; HUMAN; LARYNX SPASM; LEUKEMIA; LOW DRUG DOSE; MYELOPROLIFERATIVE DISORDER; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; ONCOGENE C MYB; PLURIPOTENT STEM CELL; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; PRURITUS; PUBERTY; QUALITY OF LIFE; QUANTITATIVE TRAIT LOCUS; REVIEW; SICKLE CELL ANEMIA; SIDE EFFECT; URTICARIA; WEIGHT GAIN; ANIMAL; BLOOD; CLASSIFICATION; GENETICS; METABOLISM;

ANIMALS; CLINICAL TRIALS AS TOPIC; FETAL HEMOGLOBIN; GENE EXPRESSION REGULATION; HEMOGLOBINOPATHIES; HUMANS;

EID: 67651015956     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-008-0637-y     Document Type: Review

References (245)

1. Bank A (2006) Regulation of human fetal hemoglobin: New players, new complexities. Blood 107:435-443
2. Grosveld F, Von Assendelft GB, Greaves DR, Kollia G (1987) Position-independent, high-level expression in the human beta-globin gene in transgenic mice. Cell 51:975-985
3. Goodwin AJ, Mc Inerney JM, Glander MA, Pomerantz O, Lowrey CH (2001) In vivo formation of a human beta-globin locus control region core elelemt requires binding sites for multiple factors including GATA-1, NF-E2, erythroid Kruppel-like factor, and Sp1. J Biol Chem 276:26883-26892
4. Carter D, Chakalova L, Osborne CS, Day YF, Fraser P (2002) Long-range chromatin regulating interactions in vivo. Nat Genet 32:623-626
5. Palstra RJ, Tolhuis B, Splinter E, Mijmeijer R, Grosveld F, De Laat W (2003) The β-globin nuclear compartment in development and erythroid differentiation. Nat Genet 35:190-194
6. Patrinos GP, De Krom M, De Boer E (2004) Multiple interactions between regulatory regions are required to stabilize an active chromatin hub. Genes Dev 18:1495-1509
7. Tolhuis B, Palstra RJ, Splinter E, Grosveld F, De Laat W (2002) Looping and interaction between hypersensitive sites in the active beta-globin locus. Mol Cell 10:1453-1465
8. Simonis M, Klous P, Splinter E, Mashkin Y, Willemsen R, De Witt E, Van Steensel B, De Laat W (2006) Nuclear organization of active and inactive chromatin domains uncovered by chromosome conformation capture-on-chip (4C). Nat Genet 38:1348-1354
9. Drissen R, Palstra RJ, Gillemans N, Splinter E, Grosveld F, Philipsen S, De Laat W (2004) The active spatial organization of the beta-globin locus requires the transcription factor EKLF. Genes Dev 18:2485-2490
10. Kooren J, Palstra TJ, Klous P, Splinter E, Von Lindern M, Grosveld F, De Laat W (2007) Beta-globin active chromatin Hub formation in differentiating erythroid cells and in p45 NF-E2 knock-out mice. J Biol Chem 282:16544-16552
11. Layon ME, Ackley CJ, West RJ, Lowrey CH (2007) Expression of GATA-1 in a non-hemopoietic cell line induces β-globin locus control region chromatin structure remodeling and an erythroid pattern of gene expression. J Mol Biol 366:737-744
12. Song SH, Hou C, Dean A (2008) A positive role for NLI/Ldb1 in long-range β-globin locus control region function. Mol Cell 28:810-822
13. Hanscombe O, Whyatt D, Fraser P, Yannoutsos N, Greaved D, Dillon N, Grosveld F (1991) Importance of globin gene order for correct developmental expression. Genes Dev 5:1387-1394
14. Peterson R, Stamatoyannopoulos G (1993) Role of gene order in developmental control of human γ- and β-globin gene expression. Mol Cell Biol 13:4836-4843
15. Tanimoto K, Liu Q, Bungert J, Engel JD (1999) Effects of altered gene order or orientation of the locus control region on human β-globin gene expression in mice. Nature 398:344-348
16. Harju S, Navis PA, Stamatoyannopoulos G, Peterson KR (2005) Genome archtecture of the human β-globin locus affects developmental regulation of gene expression. Mol Cell Biol 25:8765-8778
17. Forget BG (1998) Molecular basis of hereditary persistence of fetal hemoglobin. Ann N Y Acad Sci 850:38-44
18. Berry M, Grosveld F, Dillon N (1992) A single point mutation is the cause of the Greek form of hereditary persistence of fetal hemoglobin. Nature 358:499-502
19. Peterson KR, Li QL, Clegg CH, Furukawa T, Navas PA, Norton EJ, Kimbrough TG, Stamatoyannopoulos G (1995) Use of yeast artificial chromosomes (YACs) in studies of mammalian development production of beta-globin locus YAC mice carrying human globin developmental mutants. Proc Natl Acad Sci U S A 92:5655-5699
20. Liu LR, Du ZW, Zhao HL, Liu XL, Huang XD, Shen J, Ju L, Fang FD, Zhang JW (2005) T to C substitution at -175 or -173 of the γ-globin promoter affects GATA-1 and Oct-1 binding in vitro differently, but can independently reproduce the hereditary persistence of fetal hemoglobin phenotype in transgenic mice. J Biol Chem 280:7452-7459
21. Olave IA, Doneanu C, Fang X, Stamatoyannopoulos G, Li C (2007) Purification and identification of proteins that bind to the hereditary persistence of fetal hemoglobin mutation in the γ-globin gene promoter. J Biol Chem 282:853-862
22. Fang X, Han H, Stamatoyannopoulos G, Li Q (2004) Developmentally specific role of the CCAAT box in regulation of human γ-globin gene expression. J Biol Chem 279:5444-5449
23. Katsantoni EZ, Langeveld A, Wai A, Drobek D, Grosveld F, Anagnou N, Strouboulis J (2003) Persistent γ-globin expression in adult transgenic mice is mediated by HPFH-2, HPFH-3 and HPFH-6 breakpoint sequences. Blood 102:3412-3419
24. Chakalova L, Osborne C, Dai YF, Goyenechea B, Metaxotou-Movromati A, Kattamis A, Kattamis C, Fraser P (2005) The Corfu δβ thalassemia deletion disrupts γ-globin gene silencing and reveals post-transcriptional regulation of HbF expression. Blood 105:2154-2160
25. Garner C, Tatu T, Reittie JE (2000) Genetic influences on F cells and other hematologic variables: A twin heritability study. Blood 95:342-346
26. Garner C, Tatu T, Game L (2002) A candidate gene study of F cell levels in sibling pairs using a joint linkage and association analysis. Gene Screen 1:9-14
27. Gγ globin production. Blood 66:783-787
28. Efremov DG, Domovski AJ, Baysal A, Ye Z, Adekile AD, Ribeiro ML, Schilirý G, Altay C, Gurgey A, Efremov GD, Huisman THJ (1994) Possible factors influencing the haemoglobin and fetal hemoglobin levels in patients with β-thalassemia due to homozygosity for the IVS-1-6 (T a C) mutation. Br J Haematol 86:824-830
29. Patrinos GP, Kollia P, Loutradi-Anagnostou A, Loukopulos D, Papadakis MN (1998) The Cretan type of non-deletional hereditary persistence of fetal hemoglobin [A γ-158C a T] results from two independent gene conversion events. Hum Genet 102:629-634
30. Thein SL (2008) Genetic modifiers of the β-hemoglobinopathies. Brit J Haematol 141:357-366
31. Dover GJ, Smith KD, Chang YC (1992) Fetal hemoglobin levels in sickle cell disease and normal individuals are partially controlled by an X-linked gene located at Xp22.2. Blood 80:816-824
32. Craig JE, Rochette J, Fisher CA (1996) Dissecting the loci controlling fetal hemoglobin production on chromosome 11p and 6q by the regressive approach. Nat Genet 12:58-64
33. Garner C, Tatu T, Best S, Creary L, Thein SL (2002) Evidence for genetic interaction between the beta-globin complex and chromosome 8q in the expression of fetal hemoglobin. Am J Hum Genet 70:793-799
34. Close J, Game L, Clark BE, Bergounioux J, Gerovassili A, Thein SL (2004) Genome annotation of a 1.5 Mb region of human chromosome 6q23 encompassing a quantitative trait locus for fetal hemoglobin expression in adults. BMC Genomics 5:33-39
35. Jiang J, Best S, Menzel S, Silver N, Lai M, Surdulescu GL, Spector TD, Thein SL (2006) cMYB is involved in the regulation of fetal hemoglobin production in adults. Blood 108:1077-1083
36. Thein SL, Menzel S, Peng X, Best S, Jiang J, Close J (2007) Intergenic variants of HBS1L_MYB are responsible for a major quantitative trait locus on chromosome 6q23 influencing fetal hemoglobin levels in adults. Proc Natl Acad Sci U S A 104:11346-11351
37. Menzel S, Jiang J, Silver N, Gallagehr J, Cunningham J, Surdulescu G, Lathrop M, Farral M, Spector TD, Thein SL (2007) The HBS1L-MYB intergenic region on chromosome 6q23 influences erythrocyte, platelet, and monocyte counts in humans. Blood 110:3624-3626
38. Menzel S, Garner C, Gut I, Matsuda F, Yamaguchi M, Heath S, Foglio M, Zelenika D, Boland A, Rooks H, Best H, Spector TD, Farral M, Lathrop M, Thein SL (2007) QTL influencing F cell production maps to a gene encoding a zinc finger protein on chromosome 2p15. Nature Genet 39:1197-1199
39. Ueda M, Galanello R, Sanna S, Lettre G, Sankran VG, Chen W, Cao A (2008) Genome-wide association study shows BCL11AA association and persistent fetal hemoglobin and amelioration of the phenotype of β-thalassemia. Proc Natl Acad Sci U S A 105:1620-1625
40. Litt MD, Simpson M, Recillas-Targa F, Prioleau MN, Felsenfeld G (2001) Transitions in histone acetylation reveal boundaries of three separately regulated neighboring loci. EMBO J 20:2224-2235
41. Bulger M, Schubeler D, Bender MA (2003) A complex chromatin landscape revealed by patterns of nuclease sensitivity and histome modification within the mouse beta-globin locus. Mol Cell Biol 23:5234-5244
42. Forsberg EC, Downs KM, Christensen HM, Im H, Nuzzi PA, Bresnick EH (2000) Developmentally dynamic histone acetylation pattern of a tissue-specific chromatin domain. Proc Natl Acad Sci U S A 97:14494-14499
43. Schubeler D, Francastel C, Cimborra DM, Reik A, Martin DI, Groudine M (2000) Nuclear localization and histone acetylation: A pathway for chromatin opening and transcriptional activation of the human beta-globin locus. Genes Dev 14:940-950
44. Yin W, Barken G, Fanf X, Xiang P, Cao H, Stamatoyannopoulos G, Li Q (2007) Histone acetylation at the human β-globin locus changes with developmental age. Blood 110:4101-4107
45. Kransdorf EP, Wang SZ, Zhu SZ, Langston TB, Rupon JW, Ginder GD (2006) MBD2 is a critical component of a methyl cytosine-binding protein complex isolated from primary erythroid cells. Blood 108:2836-2845 from primary erythroid cells. Blood 108:2836-2845
46. Lavelle D, Vaitkus K, Hankewych M, Singh M, De Simone J (2005) Developmental changes in DNA methylation and covalent histone modifications of chromatin associated with the epsilon-, gamma, and beta-globin. Gene promoters in Pablo anubis. Blood Cells Mol Dis 36:269-278
47. Rupon JW, Wang SZ, Gaensler K, Lloyd J, Ginder GD (2006) Methyl binding domain protein 2 mediated gamma-globin silencing in adult human beta YAc transgenic mice. Proc Natl Acad Sci U S A 103:6617-6622
48. Mabaera R, Richardson CA, Johnson K, Hsu M, Fiering S, Loerey CH (2007) Developmental- and differentiation-specific patterns of human γ- and β-globin promoter DNA methylation. Blood 110:1343-1352
49. Duan JL, Fang X, Rohde A, Han H, Stamatoyannopoulos G, Li Q (2002) Developmental specificity of recruitment of TBP to the TATA box of the human β-globin gene. Proc Natl Acad Sci U S A 99:5509-5514
50. Zhou W, Clouston DR, Wang X, Cerruti L, Cunningham JM, Jane SM (2000) Induction of human fetal globin gene expression by a nover erythroid factor, NF-E4. Mol Cell Biol 20:7662-7672
51. Jane SM, Nienhuis AW, Cunningham JM (1995) Hemoglobin switching in man and chicken is mediated by a heteromeric complex between the ubiquitous transcription factor CP2 and a developmental specific protein. EMBO J 14:97-105
52. Jane SM, Ney PA, Vanin EF, Gumucio DL, Nienhuis AW (1992) Identification of a stage selector element in the human γ-globin gene promoter that fosters preferential interaction with the 5′-HS2 enhancer when in competition with the β-promoter. EMBO J 11:2961-2969
53. Ristaldi MS, Drabek D, Gribnau J, Poddie D, Yannoutsous N, Cao A, Grosveld F, Imam A (2001) The role of the -50 region of the human γ-globin gene in switching. EMBO J 20:5242-5249
54. Zhou WL, Clouston DR, Wang X, Cerruti L, Cunningham JM, Jane SM (2007) Induction of human fetal globin gene expression by a novel erythroid factor. Mol Cell Biol 20:7662-7672
55. Zhao Q, Zhou W, Rank G, Sutton R, Wang X, Cumming H, Cerruti L, Cunningham JM, Jane SM (2006) Repression of human γ-globin gene expression by a short isoform of the NF-E4 protein is associated with loss of NF-E2 and RNA poilymerase II recruitment to the promoter. Blood 107:2138-2145
56. Mavilio F, Giampaolo A, Care A, Migliaccio G, Calandrini M, Russo G, Pagliardi GL, Mastroberardino G, Marinucci M, Peschle C (1983) Molecular mechanisms of human hemoglobin switching: Selective endermethylation and expression of globin gene in embryonic, fetal and adult erythroblasts. Proc Natl Acad Sci U S A 80:6907-6911
57. Duan Z, Stamatoyannopoulos G, Li Q (2001) Role of NF-Y in in vivo regulation of gamma-globin gene. Mol Cell Biol 21:3083-3095
58. Fang X, Han H, Stamatoyannopoulos G, Li Q (2004) Developmentally specific role of the CCAAT box in regulation of human γ-globin gene expression. J Biol Chem 279:5444-5449
59. Tanabe O, Katsuoka F, Campbell AD, Song W, Yamamoto M, Tanimoto K, Engel JD (2002) An embryonic/fetal β-type globin gene repressor contains a nuclear receptor TR2/TR4 heterodimer. EMBO J 13:3434-3442
60. Tanabe O, McPhee D, Kobayashi S, Shen Y, Brandt W, Jiang X, Campbell AD, Chen YT, Chang C, Yamamoto M, Tanimoto K, Engel JD (2007) Embryonic and fetal beta-globin gene repression by the orphan nuclear receptors, TR2 and TR4. EMBO J 26:2295-2306
61. Tanabe O, Shen Y, Liu Q, Campbell AD, Kuroha T, Yamamoto M, Engel JD (2007) The TR2 and TR4 orphan nuclear receptors repress Gata1 transcription. Genes Dev 21:2832-2844
62. Omori A, Tanabe O, Engel JD, Fukamizu A, Tanimoto K (2005) Adult stage gamma-globin silencing is mediated by a promoter direc repeat element. Mol Cell Biol 25:3443-3451
63. Ryan TM, Sun CW, Ren J, Townes TM (2002) Human gamma-globin gene promoter element regulates beta-globin gene developmental specificity. Nucleic Ac Res 28:2736-2740
64. Sargent TG, Lloyd JA (2001) The human gamma globin TATA and CACCC elements have key, distinct roles in suppressing beta-globin gene expression in embryonic/fetal development. J Biol Chem 276:41817-41824
65. Li Q, Fang X, Olava I, Han H, Yu M, Xiang P, Stamatoyannopoulos G (2006) Transcriptional potential of the γ-globin gene is dependent on the CACCC box in a developmental stage-specific manner. Nucleic Acids Res 34:3909-3916
66. Perkins AC, Sharpe AH, Orkin SH (1995) Lethal beta-thalassemia in mice lacking the erythroid CACCC-transcription factor EKLF. Nature 375:318-322
67. Zhou D, Poulik KM, Ren J, Sun CW, Townes TM (2006) Differential binding of erythroid Kruppel-like factor to embryonic/fetal globin gene promoters during development. J Biol Chem 281:16052-16057
68. Zhang P, Basu P, Redmond LC, Morris PE, Rupon JW, Ginder GD, Lloyd JA (2005) A functional screen for Kruppel-like factors that regulate the human gamma-globin gene through the CACCC promoter element. Blood Cells Mol Dis 35:227-235
69. Hu JH, Navas P, Cao H, Stamatoyannopoulos G, Song CZ (2007) Systematic RNAi studies on the roel of Sp/KLF factors in globin gene expression and erythroid differentiation. J Mol Biol 366:1064-1073
70. Asano H, Li XS, Stamatoyannopoulos G (1999) FKLF, a novel Kruppel-like factor that activates human embryonic and fetal α-like globin genes. Mol Cell Biol 19:3571-3579
71. Asano H, Li XS, Stamatoyannopoulos G (2000) FKLF-2: A novel Kruppel-like transcriptional factor that activates globin and other erythroid lineage genes. Blood 95:3578-3584
72. Emery DW, Gravillidis G, Asano H, Stamatoyannopoulos G (2007) The transcription factor KLF11 can induce gamma-globin gene expression in the setting of in vivo adult erythropoiesis. J Cell Biochem 100:1045-1055
73. Liu LR, Du ZW, Zhao HL, Liu XL, Huang XD, Shen J, Ju L, Fang FD, Zhang JW (2005) T to C substitution at -175 or -173 of the γ-globin promoter affects GATA-1 and Oct-1 binding in vitro differently, but can independently reproduce the hereditary persistence of fetal hemoglobin phenotype in transgenic mice. J Biol Chem 280:7452-7459
74. Harju-Baber S, Costa FC, Fedosyuk H, Neades R, Peterson KR (2008) Silencing of A[gamma]-globin gene expression during adult definitive erythropoiesis mediated by GATA-1-FOG-1-Mi2 complex binding at the -566 GATA site. Mol Cell Biol 28:3101-3113
75. O'Neill D, Shoetz SS, Lopez RA, Castle M, Rabinowitz L, Shor E, Krawchuck D, Goll MG, Renz M, Seelig HP, Han S, Seong RH, Park SD, Agalioti T, Munshi N, Thanos D, Erdjument-Bromage H, Tempst P, Bank A (2000) A ikaros-containing chromatin-remodeling complex in adult-type erythroid cells. Mol Cell Biol 20:7572-7582
76. O'Neill D, Yang J, Erdjument-Bromage H, Bornschlegel K, Tempst P, Bank A (1999) Tissue-specific and developmental stage-specific DNA binding by a mammalian SWI/SNF complex associated with human fetal-to-adult globin gene switching. Proc Natl Acad Sci U S A 96:349-354
77. Lopez RA, Schoetz D, De Angelis K, O'Neill D, Bank A (2002) Multiple hematopoietic defects and delayed globin switching in Ikaros null mice. Proc Natl Acad Sci U S A 99:602-607
78. Papathanasiou P, Perkins AC, Cobb BS, Ferrini R, Sridharan R, Hoyne GF, Nelms KA, Smale ST, Goodnow CC (2003) Widespread failure of hematolymphoid differentiation caused by a recessive niche-filling allele of the Ikaros transcription factor. Immunity 19:131-144
79. Keys JR, Tallack MR, Zhou Y, Papathanasiou P, Goodnow CC, Goensler KM, Crossley M, Dekker J, Perkins AC (2008) A mechanism for Ikaros regulation of human hemoglobin switching. Br J Haematol 141:398-406
80. Chakalova L, Carter D, Fraser P (2004) RNA fluorescence in situ hybridization tagging and recovery of associated proteins to analyze in vivo chromatin interactions. Methods Ezymol 375:479-493
81. De Laat W, Klous P, Kooren J, HNoordmeer D, Palstra RJ, Simonis M, Splinter E, Grosveld F (2008) Three-dimensional organization of gene expression in erythroid cells. Curr Tol Dev Biol 82:117-139
82. Drissen R, Palstra RJ, Gillemans N, Splinter E, Grosveld F, Philipsen S, De Laat W (2004) Genes Dev 18:2485-2490
83. Vakoc CR, Letting DL, Gheldof N, Sawado T, Bender MA, Groudine M, Weiss MJ, Dekker J, Blobel GA (2006) Proximity among distant regulatory elements at the beta-globin locus requires GATA-1 annd FOG-1. Mol Cell 17:453-462
84. Kooren J, Palstra TJ, Klous P, Splinter E, Von Lindern M, Grosveld F, De Laat W (2007) Beta-globin active chromatin Hub formation in differentiating erythroid cells and in p45 NF-E2 knock-out mice. J Biol Chem 282:16544-16552
85. Watson J, Stahman AW, Bilello FP (1948) The significance of the paucity of sickle cells in newborn Negro infants. Am J Med Sci 215:419-423
86. Gambari R, Fibach E (2007) Medicinal chemistry of fetal hemoglobin inducers for treatment of β-thalassemia. Curr Med Chem 14:199-212
87. Singh M, Lavelle D, Vaitkus K, Mahmud N, Hankewych M, DeSimone J (2007) The gamma-globin gene promoter progressively demethylates as the hematopoietic stem progenitor cells differentiate along the erythroid lineage in baboon fetal liver and adult bone marrow. Exp Hematol 35:48-55
88. + thalassemia. N Engl J Med 307:1469-1475
89. Dover GJ, Charache SH, Boyer SH, Talbot CC, Smith KD (1983) 5-Azacytidine increases fetal hemoglobin production in a patient with sickle cell disease. Progr Clin Biol Res 134:475-488
90. Stamatoyannopoulos G, Veith R, Galanello R, Papayannopoulou T (1985) Hb F production in stressed erythropoiesis: Observations and kinetic models. Ann N Y Acad Sci 445:188-197
91. Christman JK (2002) 5-Azacytidine and 5-Aza-2′-deoxycitine as inhibitors of DNA methylation: Mechanicistic studies and their implications for cancer therapy. Oncogene 21:5483-5895
92. De Simone J, Heller P, Hall L, Zwiers D (1982) 5-Azacytidine stimulates fetal hemoglobin synthesis in anemic babbons. Proc Natl Acad Sci U S A 79:4428-4431
93. Saunthararajah Y, Lavelle D, De Simone J (2004) DNA hypo-methylating agents and sickle cell disease. Br J Haematol 126:629-636
94. Mabaera R, Greene MR, Richardson CA, Conine SJ, Korul CD, Lowrey CH (2008) Neither DNA hypomethylation nor changes in the kinetics of erythroid differentiation explain 5-azacytidine's ability to induce human fetal hemoglobin. Blood 111:411-420
95. Lavelle D, Saunthararajah Y, DeSimone J (2008) DNA methylation and mechanism of action of 5-azacytidine. Blood 111:2845
96. De Simone J, Heller P, Hall L, Zwiers D (1982) 5-Azacytidine stimulates fetal hemoglobin synthesis in anemic babbons. Proc Natl Acad Sci U S A 79:4428-4431
97. Ley TJ, DeSimone J, Noguchi T, Turner PH, Schechter AN, Heller P, Nienhuis AW (1983) 5-Azacytidine increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia. Blood 62:370-380
98. Charache S, Dover G, Smith K, Talbot Jr CC, Moyer M, Boyer S (1983) Traetment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the gamma-delta-globin gene complex. Proc Natl Acad Sci U S A 80:4842-4846
99. Carr BI, Reilly JG, Smith SS, Winberg C, Riggs A (1984) The tumoreginicity of 5-azacytidine in the male Fisher rat. Carcinogenesis 5:1583-1590
100. Saunthararajah Y, Hillery CA, Lavelle D, Molokie R, Dorn L, Bressler R, Gazanova S, Chen YH, Hoffman R, DeSimone J (2003) Effects of 5-aza-2′-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood 102:3865-3870
101. Koshy M, Dorn L, Bressler L, Lavelle D, Talischy N, Hoffman R, van Overveld W, DeSimone J (2000) 2-Deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood 96:2379-2384
102. DeSimone J, Koshy M, Dorn L, Lavelle D, Bressler L, Molokie R, Talischy N (2002) Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Blood 99:3905-3908
103. Saunthararajah Y, Malokie R, Saraf S, Sidhwani S, Gowhari M, Vara S, Lavelle D, DeSimone J (2008) Clinical effectiveness of decitabine in severe sickle cell disease. Br J Haematol 141:126-129
104. Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G (2007) Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol 25:4519-4521
105. Yin W, Barkess G, Fang X, Xiang P, Cao H, Stamatoyannopoulos G, Li C (2007) Histone acetylation at the human β-globin locus changes with developmental age. Blood 110:4101-4107
106. Cao H (2004) Pharmacological induction of fetal hemoglobin synthesis using histone deacetylase inhibitors. Hematology 9:223-233
107. Pace BS, Qian X, Sangerman J et al (2003) p38 MAP kinase is required for fetal hemoglobin induction by butyrate and trichostatin. Exp Hematol 11:1089-1096
108. Cao H, Stamatoyannopoulos G, Jung M (2004) Induction of human gamma globin gene expression by histone deacetylase inhibitors. Blood 103:701-709
109. Johnson J, Hunter R, McElveen R, Qian XH, Baliga BS, Pace BS (2005) Fetal hemoglobin induction by the histone deacetylase inhibitor, scriptaid. Cell Mol Biol 51:229-238
110. Witt O, Monkemeyer G, Ronndahl G, Erdlenbruch B, Reinhardt D, Kanbach K, Pekrun A (2003) Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin. Blood 101:2001-2007
111. Tamura K, Sudo T, Senftleben U, Dadak AM, Johnson R, Karin M (2000) Requirement for p38alpha in erythropoietin expression: A role for stress kinases in erythropoiesis. Cell 102:221-231
112. Wei GH, Zhao GW, Song W, Hao DL, Lu X, Liu DP, Liang CC (2007) Mechanism of human γ-globin transcriptional induction by apicidin involves p38 signaling to chromatin. Biochem Biophys Res Commun 363:889-894
113. Mankidy R, Faller DV, Mabaera R, Lowrey CH, Boosalis MS, White GL, Castaneda SA, Perrine SP (2006) Sort-chain fatty acids induce gamma-globin gene expression by displacement of a HDAC3-NCoR repressor complex. Blood 108:3179-3186
114. Sangerman J, Lee MS, Yao X, Oteng E, Hsias CH, Li W, Zeih S, Ofori-Acquah S, Pace BS (2006) Mechanism for fetal hemoglobin induction by histone deacetylase inhibitors involves γ-globin activation by CREB1 and ATF-2. Blood 108:3590-3599
115. Collins AF, Dover GJ, Luban NLC (1994) Increased fetal hemoglobin production in patients receiving valproic acid for epilepsy. Blood 84:1690-1691
116. Liakopoulou E, Blau CA, Li Q, Josephson B, Wolf JA, Fournarakis B, Raisys V, Dover G, Papayannopoulou T, Stamatoyannopoulos G (1995) Stimulation of fetal hemoglobin production by short-chain fatty acids. Blood 86:3227-3235
117. Wood A, Davies SC (1995) Induction of hemoglobin F in sickle cell anemia (SS) by sodium valproate [abstract]. Blood 86:1419
118. Salim KA, Salim A (1995) Therapy with sodium valproate is as effective as that with hydroxyurea in preventing painful crisis of sickle cell disease. Blood 86:1419 (abstract)
119. Selby R, Nisbet-Brown E, Basran RK, Chang L, Olivieri NF (1997) Valproic acid and augmentation of fetal hemoglobin in individuals with and without sickle cell disease. Blood 89:891-893
120. Witt O, Monkemeyer G, Ronndahl G, Erdlenbruch B, Reinhardt D, Kanbach K, Pekrun A (2003) Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin. Blood 101:2001-2007
121. Witt O, Monkemeyer S, Kanbach K, Pekrun A (2002) Induction of fetal hemoglobin synthesis by valproate: Modulation of MAP kinase pathways. Am J Haematol 71:45-46
122. Roondahl G, Monkemeyer S, Schulze S, Pekrun A, Eikel D, Nau H, Witt O (2006) Novel valproic acid derivatives with hemoglobin F inducing activity. Am J Haematol 81:374-376
123. Mai A, Jelicic K, Rotili D, Di Noia A, Alfani E, Valente S, Altucci L, Nebbioso A, Massa S, Galanello R, Brosch G, Migliaccio AR, Migliaccio G (2007) Identification of two new synthetic histone deacetylase inhibitors that modulate globin gene expression in erythroid cells from healthy donors and patients with thalassemia. Mol Pharmacol 72:1111-1123
124. Papayannopoulou T, Nakamoto B, Kurachi S, Nelson R (1987) Analysis of the erythroid phenotype of HEL cells: Clonal variation and the effect of inducers. Blood 70:1764-1772
125. Ginder GD, Whitters MJ, Pohlman JK (1984) Activation of a chicken embryonic globin gene in adult erythroid cells by 5-azacytine and sodium butyrate. Proc Natl Acad Sci U S A 81:3954-3958
126. Perrine SP, Greene MF, Faller DV (1985) Delay in the fetal globin switch in infants of diabetic mothers. N Engl J Med 312:334-338
127. Bard H, Prosmanne J (1985) Relative rates of fetal hemoglobin and adult hemoglobin synthesis in cord blood of infants of insulin-dependent diabetic mothers. Pediatrics 75:1143-1147
128. Fibach E, Premakala P, Rodgers GP, Samid D (1993) Enhanced fetal hemoglobin production by phenyacetate and 4-phenylbutyrate in erythroid precursors serived from normal donors and patients with sickle cell anemia and β-thalassemia. Blood 82:2203-2210
129. Constantoulakis P, Papayannopoulou T, Stamatoyannopoulos G (1998) alpha-Amino-N-butyric acid stimulates fetal hemoglobin in the adult. Blood 72:1961-1967
130. Constantoulakis P, Knitter G, Papayannopoulou T (1989) On the induction of fetal hemoglobin by butyrates: In vivo and in vitro studies with sodium butyrate and comparison of combination treatments with 5-AzaC and AraC. Blood 74:1963-1971
131. Perrine SP, Rudolph A, Faller DV, Roman C, Cohen RA (1986) Butyrate infusions in the ovine fetus delay the biologic clock for globin gene switching. Proc Natl Acad Sci U S A 85:8540-8545
132. McDonagh KT, Nienhuis AW (1992) Induction of the human γ-globin gene promoter in K562 cells by sodium butyrate. Reversal of repression by CCAAT displacement protein. Blood 78:255a (abstract, suppl 1)
133. Safaya S, Ibrahim A, Reider RF (1994) Augmentation of γ-globin gene promoter activity by carboxylic acids and components of the human β-globin locus control region. Blood 84:3929-3938
134. McCaffrey PG, Newsome DA, Fibach E, Yoshida M, Su MS (1997) Induction of γ-globin by histone deacetylase inhibitors. Blood 90:2075-2083
135. Ikuta T, Kan YW, Swerdlow PS, Faller DV, Perrine SP (1998) Alterations in protein-DNA interactions in the gamma-globin gene promoter in response to butyrate therapy. Blood 92:2924-2933
136. Witt O, Sand K, Pekrun A (2000) Butyrate-induced erythroid differentiation of human K562 leukemia cells involves inhibition of ERK and activation of p38 MAP kinase pathways. Blood 95:2391-2396
137. Hsiao CH, Li W, Lou TF, Baliga BS, Pace BS (2006) Fetal hemoglobin induction by histone deacetylase inhibitors involves generation of reactive oxygen species. Exp Hematol 34:264-273
138. Weinberg RS, Ji X, Sutton M, Perrine S, Galperin Y, Li Q, Liebhaber SA, Stamatoyannopoulos G, Atweh GF (2005) Butyrate increases the efficiency of translation of γ-globin mRNA. Blood 105:1807-1809
139. Fathallah H, Weiberg RS, Galperin Y, Sutton M, Atweh GF (2007) Role of epigenetic modifications in normal globin gene regulation and butyrate-mediated induction of fetal hemoglobin. Blood 110:3391-3397
140. Perrine SP, Ginder GD, Faller DV, Dover GH, Ikuta T, Witkowska HE, Cai SP, Vickinsky EP, Olivieri NF (1993) A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. N Engl J Med 328:81-86
141. Sher GD, Ginder GD, Little J, Yang S, Dover G, Olivieri NF (1995) Extended therapy with intravenous arginine butyrate in patients with β-hemoglobinopthies. N Engl J Med 332:1606-1610
142. Atweh GF, Sutton M, Nassif I, Bosalis V, Dover G, Wallenstein S, Wright E, McMahon L, Stamatoannopoulos G, Faller DV, Perrine SP (1999) Sustained induction of fetal hemoglobin b pulse butyrate therapy in sickle cell disease. Blood 93:1790-1797
143. Frenette PS, Atweh GF (2007) Sickle cell disease: Old discoveries, new concepts, and future promise. J Clin Invest 117:850-858
144. Dover DJ, Brusilow S, Charache S (1994) Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood 84:339-343
145. Resar LM, Segal JB, Fitzpatric LK, Friedman A, Brusilow SW, Dover GJ (2002) Induction of fetal hemoglobin synthesis in children with sickle cell anemia on low-dose sodium phenylbutyrate therapy. J Pediatr Hematol Oncol 224:737-741
146. Collins AF, Pearson HA, Gardina P, McDonagh KT, Brusilow SW, Dover GJ (1999) Oral sodium phenylbutyrate in homozygous β-thalassemia: A clinical trial. Blood 85:43-49
147. Reich S, Buhrere C, Henze G, Ohlendorf D, Mesche M, Sinha P, Kage A, Muller C, Vetter B, Kulozik AE (2000) Oral isobutyramide reduces transfusion requirements in some patients with homozygous β-thalassemia. Blood 96:3357-3363
148. Letvin NL, Linch DC, Beardsle P, McIntre KW, Nathan DG (1984) Augmentation of fetal hemoglobin poduction in anemic monkeys by hydroxurea. N Engl J Med 310:869-878
149. Veith R, Galanello R, Papayannopoulou T, Stamatoannopoulos G (1984) Stimulation of F-cell production in patients with sickle-cell anemia treated with cytabarine or hydroxyurea. N Engl J Med 313:1571-1578
150. Charache S, Dover GJ, Moyer MA, Moore JW (1987) Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia. Blood 69:109-118
151. Charache S, Dover GJ, Moore RD, Eckert S, Ballas SK, Kosh M, Milner PF, Orringer EP, Phillips G, Platt OS, Thomas GH (1992) Hydroxyurea: Effects on hemoglobin F production in patients with sickle cell anemia. Blood 79:2555-2565
152. Fibach E, Burke LP, Schechter AN, Noguchi CT, Rodgers GP (1993) Hydroxyurea increase fetal hemoglobin in cultured erythroid cells derived from normal individuals and patients with sickle cell anemia or β-thalassemia. Blood 81:1630-1635
153. Ikuta T, Ausenda S, Cappellini MD (2001) Mechanism for fetal globin gene expression: Role of the soluble guanylate cyclase-cGMP.dependent protein kinase pathway. Proc Natl Acad Sci U S A 98:1847-1852
154. Cokic VP, Smith RD, Beleslin-Cokic BB (2003) Hydroxyurea induces fetal hemoglobin by the nitric oxide.dependent activation of soluble guanylyl cyclase. J Clin Invest 111:231-239
155. Nahavandi M, Tavakkoli F, Wyche MQ, Perlin E, Winter WP, Castro O (2002) Nitric oxide and cyclic GMP levels in sickle cell patients receiving hydroxyurea. Br J Haematol 119:885-857
156. Conran N, Oresco-Santos C, Acosta HC, Fattori A, Saad ST, Costa FF (2004) Increased soluble guanylate cyclase activity in the red blood cells of sickle cell patients. Br J Haematol 124:547-554
157. Cokic VP, Andric SA, Stojikovic SS, Noguchi CT, Schechter AN (2008) Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells. Blood 111:1117-1123
158. Keefer JR, Scheidenrlith TA, Mays A, Purvis JH, Dover GJ, Smith KD
159. Baily L, Kuroyanagi Y, Franco-Penteado CF, Conran N, Costa FF, Ausenda S, Cappellini MD, Ikuta T (2007) Expression of the γ globin gene is sustained by the cAMP-dependent pathway in β-thalassemia. Br J Haematol 138:382-395
160. Tang DC, Zhu J, Liu W, Chin K, Sun J, Chen L, Hanover JA, Rodgers GP (2005) The hydroxyurea-induced small GTP-binding protein SAR modulates gamma-globin gene expression in human erythroid cells. Blood 106:3256-3263
161. Fathallah H, Ayweh GF (2006) Induction of fetal hemoglobin in the treatment of sickle cell disease. ASH Ed Progr, pp 58-62
162. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR (1995) Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 332:1317-1322
163. Steinberg MH, Lu ZH, Barton FB, Terrin ML, Charache S, Dover GJ (1997) Fetal hemoglobin in sickle cell anemia: Determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. Blood 89:1078-1088
164. Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N (2003) Effect of hydroxyurea on mortality and mobidity in adult sickle cell anemia. JAMA 289:1645-1652
165. De Baun MR, Field JJ (2007) Limitations of clinical trials in sickle cell disease: A case study of the Multi-cebter study of Hydroxyurea (MSH) Trial and the Stroke Prevention (STOP) Trial. ASH Ed Progr, pp 482-488
166. Ballas SK, Barton FB, Waclawin MA, Swerdlow P, Eckman JR, Pegelow CH, Koshy M, Barton BA, Bonds DER (2006) Hydroxyurea ande sickle cell anemia: Effect on quality of life. Health Qual Life Outcomes 4:59
167. Bakanay SM, Dainer E, Clair B, Adekile A, Daitch L, Wells L, Holley L, Smith D, Kutlar A (2005) Mortality in sickle cell patients on hydroxyurea therapy. Blood 105:545-547
168. Lanzkron S, Strouse JJ, Wilson R, Beach MC, Haywood C, Pak HS (2008) An evidence-based review for the NIH consensus development conference on hydroxyurea for the treatment of adults with sickle cell disease. Ann Int Med 148:121-131
169. Kenney TR, Helms RW, O'Branski EE (1999) Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood 94:1550-1554
170. Haskins JS, Ware RE, Rogers ZR (2005) Long-term therapy for infants with sickle cell anemia - the HUSOFT extension study. Blood 106:2269-2275
171. Wang WC, Wynn LW, Rogers ZR, Scott JP, Lane PA, Ware RE (2001) A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. J Pediatr 139:790-796
172. Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA (2004) Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 103:2039-2045
173. Ware RE, Eggleston B, Redding-Lallinger R, Wang W, Smith-Whitley K, Daeschner C, Gee B, Styles L, Helms R, Kinney TR, Ohene-Frempong K (2002) Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood 99:10-14
174. Zimmerman SA, Schultz WH, Burgett S, Mortiez NA, Mortier NA, Ware RE (2007) Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. Blood 110:1043-1047
175. Heeney MM, Ware RE (2008) Hydroxyurea for children with sickle cell disease. Ped Clin North Am 55:483-501
176. Platt OS (2008) Hydroxyurea for the treatment of sickle cell anemia. N Engl J Med 358:1362-1369
177. Ma Q, Wyszynski DF, Farrell JJ, Kutlar A, Farrer LA, Baldwin CT, Steinberg MH (2007) Fetal hemoglobin in sickle cell anemia: Genetic determinants of response to hydroxyurea. The Pharmacogenomics J 7:386-394
178. Kunrkhaek C, Taylor JG, Zhu J, Hoppe C, Kato GJ, Rodgers JP (2008) Fetal hemoglobin response to hydroxycarbamide treatment and sar1a promoter polymorphism in sickle cell anemia. Br J Haematol 141:254-259
179. Bakanay SM, Dainer E, Clair B, Adekle A, Daitch L, Wells L, Holley L, Smith D, Kutlar A (2005) Mortality in sickle cell patients on hydroxyurea therapy. Blood 105:545-547
180. Friedirish JR, Pra D, Maluf SW, Bittar C, Mergener M, Pollo T, Kayser M, Da Silva MA, Hemniques JA, Rocha Silla LM (2008) DNA damage in blood leukocytes of individuals with sickle cell disease treated with hydroxyurea. Mutat Res 649:213-220
181. Hajjar FM, Pearson HA (1994) Pharmacologic treatment of thalassemia intermedia with hydroxyurea. J Pediatr 125:490-492
182. Zeng YT, Huang SZ, Ren ZR (1995) Hydroxyurea therapy in β-thalassemia intermedia: Improvement in haematological parameters due to enhanced β-globin synthesis. Br J Haematol 90:557-563
183. Loukopoulos D, Vaskaridou E, Stamoulakatou A (1998) Hydroxyurea therapy in thalassemia. Ann N Y Acad Sci 850:120-128
184. Hoppe C, Vichinsky E, Lewis B (1999) Hydroxyurea and sodium phenylbutyrate therapy in thalassemia intermedia. Am J Haematol 62:221-227
185. De Paula EV, Lima CS, Arruda VR (2003) Long-term hydroxyurea therapy in β-thalassemia patients. Eur J Haematol 70:151-155
186. Konstasntopoulos K, Vagiopoulos G, Kantouni R (1992) A case of spinal cord compression by extramedullary haemopoiesis in a thalassemic patient: A putative role for hydroxyurea. Haematologica 77:352-354
187. Saxon BR, Rees D, Olivieri NF (1998) Regression of extramedullary haemopoiesis and augmentation of fetal hemoglobin concentration during hydroxyurea therapy in β thalassemia. Br J Haematol 101:416-419
188. Wegener M, Debatin KM, Kohne E (2002) Treatment with hydroxyurea in thalassemia intermedia with paravertebral pseudotumours of extramedullary hematopoiesis. Ann Hematol 81:478-482
189. Gamberini MR, Fortini M, De Sanctis V (2004) Paraplegia due to spinal cord compression by the extramedullary erythropoietic tissue in a thalassemia intermedia patient with gynecomasty secondary to cirrhosis: successful treatment with hydroxyurea. Pediatr Endocrinol Rev Suppl 2:316-318
190. Singer ST, Kuypers FA, Olivieri NF (2005) E/β thalassemia study group. Fetal hemoglobin augmentation in E/β° thalassemia: clinical and haematological outcome. Br J Haematol 131:378-388
191. Fucharoen S, Siritanaratkul N, Winichagoon P (1996) Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in β-thalassemia/hemoglobin E disease. Blood 87:887-892
192. Watanapokasin Y, Chuncharunee S, Sanmund D, Kongnium W, Winichagoon P, Rodgers GP, Fucharoen S (2005) In vivo and in vitro studies of fetal hemoglobin induction by hydroxyurea in β-thalassemia/hemoglobin E patients. Exp Hematol 33:1486-1492
193. Bradai M, Abad MI, Pissard S (2003) Hydroxyurea can eliminate transfusion requirements in children with severe β-thalassemia. Blood 102:1529-1530
194. Yavarian M, Karimi M, Bakker E, Harteveld CE, Giordano PR (2004) Response to hydroxyurea treatment in Iranian transfusion-dependent β-thalassemia patients. Haematologica 89:1172-1178
195. Alebouyeh M, Moussavi F, Haddad-Deylami H, Vossough P (2004) Hydroxyurea in the treatment of major beta-thalassemia and importance of genetic screening. Ann Hematol 83:430-433
196. Dixit A, Chatterjee TT, Mishra P, Choudry DR, Makapatra M, Tyagi S, Kabra M, Saxena R, Choudry VP (2005) Hydroxyurea in thalassemia intermedia - a promising therapy. Ann Hematol 84:441-446
197. Karimi M, Darzi H, Yavarian M (2005) Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. J Pediatr Hematol Oncol 27:380-385
198. Koren A, Levin C, Dgany O, Krausnov T, Elhaisid R, Zalman L, Palmar H, Tamary H (2008) Response to hydroxuurea therapy in β-thalassemia. Am J Haematol 83:366-370
199. Bradai M, Pissard S, Abad MT, Deschartres A, Ribeil JA, Landais P, De Montalembert M (2007) Decreased tranfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. Transfusion 47:1830-1836
200. Ansari SH, Shamsi TS, Siddqui FJ, Irfan M, Perveen K, Farzana T, Panjwani VK, Yousuf A, Mehboob T (2007) Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT). J Pediatr Hematol Oncol 29:743-746
201. Zeng YT, Huang SZ, Ren ZR, Lu ZH, Zeng FY, Scechter AN, Rodgers GP (1995) Hydroxyurea therapy in β-thalassemia intermedia: Improvement in haematological parameters due to enhanced β-globin synthesis. Br J Haematol 90:557-563
202. Chui DH, Liao SK, Walker K (1998) Fetal erythropoiesis in steel mutant mice. III Defect in differentiating from BFU-E to CFU-E during early development. Blood 51:539-545
203. Nocka K, Majumder S, Chabot B (1989) Expression of c-Kit gene productrs in known cellular targets of W mutations in normal and W mutant mice. Genes Dev 3:816-826
204. Waskow C, Terszowski G, Costa C, Gassmann M, Rodelwald HR (2004) Rescue of lethal c-Kit W/W mice by erythropoietin. Blood 104:1688-1695
205. Flanagan JG, Chan DC, Leder P (1991) Transmembrane form of the kit ligand growth factor is determined by alternative splicing and is missing in the Sld mutant. Cell 64:1025-1035
206. Kapur R, Majumdar M, Xiao X, McAnrews-Hill M, Schindler K, Williams DA (1998) Signaling through the interaction of membrane-restricted stem cells factor and c-Kit receptor tyrosine kinase: Genetic evidence for a differential role in erythropoiesis. Blood 91:879-889
207. Munugalevadla V, Kapur R (2005) Role of c-kit and erythropoietin receptor in erythropoiesis. Crit Rev Oncol Hematol 54:63-75
208. Zeuner A, Pedini F, Signore M, Testa U, Pelosi E, Peschle C, De Maria R (2003) Stem cell factor protects erythroid precursor cells from chemotherapeutic agents via up-modulation of BCL-2 family proteins. Blood 102:87-93
209. Gabbianelli M, Pelosi E, Bassano E, Labbaye C, Pedtti G, Rocca E, Tritarelli E, Miller BA, Valtieri M, Testa U, Peschle C (1989) Granulocyte-macrophage colony-stimulating factor reactivates fetal hemoglobin synthesis in erythroblast clones from normal adults. Blood 74:2657-2669
210. Migliaccio AR, Migliaccio G, Brice M, Costantoulakis P, Stamatoyannopoulos G, Papayannopoulo T (1990) Influence of recombinant hematopoietins and of fetal bovine serum on the globin synthetic pattern of human BFU-E. Blood 76:1150-1158
211. Fujimori Y, Ogawa M, Clark SC, Dover DJ (1990) Serum-free culture of enriched hematopoietic progenitors reflects physiologic levels of fetal hemoglobin synthesis. Blood 75:1718-1725
212. Costantoulakis P, Nakamoto B, Papayannopoulou T, Stamatoyannopoulos G (1990) Fetal calf contains activities that induce fetal hemoglobin in adultd erythroid cell cultures. Blood 75:1862-1870
213. Miller BA, Perrine SP, Bernstein A, Lyman SD, Williams DE, Bell LL, Olivieri NF (1992) Influence of Steel Factor on hemoglobin synthesis in sickle cell disease. Blood 79:1861-1868
214. Peschle C, Gabbianelli M, Testa U, Pelosi E, Barberi T, Fossati C, Valtieri M, Leone L (1993) c-kit ligand reactivates fetal hemoglobin synthesis in serum-free culture of stringently purified human adult burst-forming unit-erythorid. Blood 81:328-336
215. Gabbianelli M, Testa U, Massa A, Pelosi E, Sposi NM, Riccioni R, Lucchetti L, Peschle C (2000) Hemoglobin switching in unicellular erythroid culture of sibling erythroid burst-forming units: Kit ligand induces a dose-dependent fetal hemoglobin reactivation potentiated by sodium butyrate. Blood 95:3555-3561
216. Wojda U, Leigh WR, Njoroge JM, Jackson KA, Natarajan B, Stitely M, Miller JL (2003) Fetal hemoglobin modulation during human erythropoiesis: Stem cell factor has "late" effects related to the expression pattern of CD117. Blood 101:492-497
217. Bhanu NV, Trice TA, Lee YT, Gautt NM, Oneal P, Schwartz JD, Noel P, Miller PL (2005) A sustained and pancellular reversal of gamma-globin gene silencing in adult human erythroid precursor cells. Blood 105:387-393
218. Von Lindern M, Zauner W, Mellitzer G, Steinlein P, Fritsch G, Huber K, Lowenberg B, Beug H (1999) The glucocorticoid receptor cooperates with the erythropoietin receptor and c-kit to enhance and sustain proliferation of erythroid progenitors in vitro. Blood 94:550-559
219. Gabbianelli M, Testa U, Massa A, Morsilli O, Saulle E, Sposi NM, Petrucci E, Mariani G, Peschle C (2003) HbF reactivation in sibling BFU-E colonies: Synergistic interaction of kit ligand with low-dose dexamethasone. Blood 101:2826-2832
220. Gabbianelli M, Morsilli O, Massa A, Pasquini L, Cianciulli P, Testa U, Peschle C (2008) Effective erythropoiesis and HbF reactivation induced by kit ligand in β-thalassemia. Blood 111:421-429
221. Bhanu NV, Trice TA, Lee YT, Miller JL (2004) A signaling mechanism for growth-related expression of fetal hemoglobin. Blood 103:1929-1933
222. Lavelle D, Molokie R, Ducksworth J, DeSimone J (2001) Effects of hydroxyurea, stem cell factor, and erythropoietin in combination on fetal hemoglobin in the baboon. Exp Hematol 29:156-162
223. Galli SJ, Iemura A, Garlick DS, Gamba-Vitalo C, Zsebo KM, Andrews RG (1993) Reversible expansion of primate mast cell populations in vivo by stem cell factor. J Clin Invest 91:148-152
224. Ando A, Martin TR, Galli SJ (1993) Effects of chronic treatment with the c-kit ligand, stem cell factor, on immunoglobulin E-depencdent anaphylaxis in mice. Genetically mast cell-deficient Sl/Sld mice acquire anaphylactis responsiveness, but the congenic normal mice do not exhibit augmented responses. J Clin Invest 92:1639-1649
225. Costa JJ, Demetri GD, Harrist TJ, Dvorak AM, Merica EA, Menchaca DM, Gringeri AJ, Schwartz LB, Galli SJ (1996) Recominant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J Exp Med 183:2681-2686
226. Crawford J, Lan D, Erwin R (1993) A phase I trial of recominant methionyl human stem cell factor (SCF) in patients with advanced non-small cell lung carcinoma (NSCLC). Proc Ann Meet Am Assoc Cancer Res 34:1257a
227. Usuki K, Iki S, Arai S, Iijima K, Takaku F, Urabe A (2005) Stable response after administration of stem cell factor combined with granulocyte colony-stimulating factor in aplastic anemia. Int J Hematol 83:404-407
228. Wadhwa PD, Lazarus HM, Koc ON (2003) Hematopoietic recovery after unrelated umbilical cord blood alloge3neic transplantation in adults treated and in vivo stem cell factor (R-Met Hu SCF) and figlastrim administration. Leuk Res 27:215-220
229. Blaise D, Faucher C, Vey N, Caraux J, Maraninchi D, Chabannon C (2000) Rescue of haemopoiesis by a combination of growth factors including stemcell factor. Lancet 356:1325-1326
230. Shpall EJ, Wheeler CA, Turner SA (1999) A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. Blood 93:2491-2501
231. Teyssier-Le Discorde M, Prost S, Nandrot C, Kirsewnbaum M (1999) Spatial and temporal mapping of c-kit and its ligand, stem cell factor expression during human embryonic hemopoiesis. Br J Haematol 107:247-253
232. Yamaguchi H, Ishii E, Saito S, Tashiro K, Fuijta I, Yoshidomi S, Ohbuto M, Arakawa K, Miyazaki S (1996) Umilical vein endothelial cells are an important source of c-kit and stem cell factor which regulate the proliferation of haemopoietic progenitor cells. Br J Haematol 94:606-611
233. Savas A, Ince S, Coskun M, Durmaz S, Yegin O (1998) Stem cell factor (SCF) levels in newborns. Am J Perinatal 15:427-429
234. Broody VC, Kovach NL, Bennet LG, Lin N, Jacobsen FW, Kidd PG (1994) Human umbilical vein endothelial cells display high-sffinity c-kit receptors and produce a soluble form of the c-kit receptor. Blood 83:2145-2152
235. Aebarjinai W, Zhu J, Gao Z, Chin K, Rodgers GP (2007) Thalidomide induces γ-globin gene expression through increased reactive oxygen species-mediated p38 MAPK signaling and histone H4 acetylation in adult erythropoiesis. Blood 110:2864-2871
236. + cells. J Clin Invest 118:248-258
237. Perrine SP (2005) Fetal hemoglobin induction- Can it cure β thalassemia? Hematology 2005:38-44
238. Quek L, Thein SL (2006) Molecular therapies in β-thalassemia. Br J Haematol 136:353-365
239. Pinto FO, Roberts I (2008) Cord blood stem cell transplantation for haemoglobinopathies. Br J Haematol 141:309-324
240. Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663-676
241. Hanna J, Werning M, Markoulaki (2007) Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 318:1920-1923
242. Yu CY, Vodyanik MA, Smaga-Otto K, Antosiewicz-Bourget J, Frane JC, Yian S, Nie J, Jousdottir GA, Ruotti V, Stewart R, Sluvkin JL, Thomson JA (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318:1917-1920
243. Lebensburger J, Person DA (2008) Progress toward safe and effective gene therapy for beta-thalassemia in sickle cell disease. Curr Opin Drug Discov Devel 11:225-232
244. Lisowski L, Sadelain M (2008) Current status of globin gene therapy for the treatment of α-thalassemia. Br J Haematol 141:335-345
245. Mancuso A, Maggio A, Renda D, Di Marzo R, Rigano P (2006) Treatment with hydroxycarbamide for intermedia thalassaemia: Decrease of efficacy in some patients during long-term follow up. Br J Haematol 133:105-106